PDS Biotechnology reported a net loss of $37.6 million for the full year ended December 31, 2024, a reduction from the $42.9 million net loss in the prior year. This improvement was primarily driven by decreased operating expenses, partially offset by increased net interest expense. The company also initiated a pivotal Phase 3 clinical trial for Versamune® HPV in HPV16-positive head and neck cancer.